Infection of resting peripheral mononuclear blood cells (PBMCs) with HIV-1 is not productive due to a block prior to integration of the provirus into the host genome. Here we show that a unique restriction is determined by the status of the glucocorticoid receptor (GR). Proviral integration increases after addition of a GR ligand. The ligand dependent effect is confined to an early time period after infection and requires GR and the GR binding viral protein Vpr. Endogenous GR and transiently expressed Vpr are localized in the cytoplasm in unstimulated PMCs and comigrate into the nucleus upon ligand addition. Thus, the predominant cytoplasmic localization of GR seems to be a specific obstacle for HIV replication. Accordingly, efficient proviral integration in a cell line with a constitutive cytoplasmic GR requires addition of a GR ligand. The data suggest that steroids can overcome the restriction on HIV provirus formation and thereby increase the reservoir of virus producing cells.
Introduction
The role of HIV receptors and coreceptors, the mechanisms leading to fusion of viral and host cell membranes, and the subsequent entry of the viral cores have been elucidated at the molecular level, leading already to new therapeutic approaches to prevent infection (reviewed in: Moore and Stevenson, 2000; Ray and Doms, 2006) . However, the steps occurring after entry are still poorly understood. It remains particularly unclear which cellular factors influence the early steps of a viral infection.
Unlike beta-and gamma-retroviruses which require cell division to allow effective infection, lentiviruses can also infect resting cells, although with lower efficiency. Several studies have shown that HIV is restricted at the post-entry stage in resting T cells and in freshly isolated PBMCs in vitro (Zack et al., 1990; Stevenson et al., 1990) . After stimulation of PBMCs with mitogens or cytokines, which promote cell proliferation and differentiation, the cells become permissive (Pomerantz et al., 1990; Rosenberg and Fauci, 1990) . The factors that restrict HIV-1 replication in unstimulated mononuclear cells are not yet clearly defined. For resting T cells it was shown that the block likely exists after reverse transcription and prior to integration of the viral genome into the host genome. It was suggested that these cells do not to allow complete reverse transcription and the viral DNA stays in a transcriptionally nonfunctional form (Blaak et al., 2000; Sonza et al., 1996; Stevenson et al., 1990) .
A number of cellular proteins have been implicated in the early block to infection. For example, it was shown that the cytidine deaminase APOBEC3G could cause high levels of hypermutations in the HIV genome (Bishop et al., 2004; Mangeat et al., 2003; Sheehy et al., 2002) . The effect is counteracted by the viral protein Vif which causes proteosomal degradation of APOBEC3G (Sheehy et al., 2003) . But APOBEC3G causes an additional severe defect at the level of reverse transcription, which is independent of its deaminase activity (Chiu et al., 2005) . In nonpermissive cells APOBEC3G resided in a low-molecularmass (LMM) complex which is converted into a high-molecularmass (HMM) complex in permissive cells upon treatment with cytokines (Chiu et al., 2005) . The underlying mechanisms leading to this recently observed block in reverse transcription are not yet clear.
On the other hand, interaction of viral accessory proteins with cellular proteins may be a major factor influencing early steps in the HIV life cycle. The viral protein Vpr, a constituent of the nucleocapsid of the infecting virus particle, is required for an efficient replication of the virus in monocytes and macrophages (Connor et al., 1995; Ayyavoo et al., 1997) . This effect is partially ascribed to its function to arrest cells in G2/M phase of the cell cycle, which is thought to provide more favourable conditions for enhanced HIV LTR driven gene expression. Additional functions of Vpr include transactivation of the HIV LTR prior to the action of Tat. HIV-1 Vpr has been shown to transactivate LTR-directed expression through its interaction with several proteins of cellular origin, including the glucocorticoid receptor (GR) (Thotala et al., 2004) . In addition to these functions, Vpr interacts with a number of transcription factors, and co-factors, including the p300/CREB binding protein and TFIIB (reviewed in: Kino and Pavlakis, 2004) . Vpr can act as a co-activator of GR on glucocorticoid responsive promoters (Felzien et al., 1998; Kino et al., 2002) , but available data question the direct stimulatory effect of GR on the HIV LTR and on HIV gene expression, since the HIV LTR does not contain a bona fide GRE (Soudeyns et al., 1993) . Although in reporter assays Vpr was also shown to transactivate the HIV-1 LTR through the host GR pathway (Vanitharani et al., 2001) . In T cells, however activation of GR was even shown to inhibit the HIV-LTR-driven gene expression (Kino et al., 2000; Mitra et al., 1995) . Alternatively, Vpr-GR complexes may rather affect the regulation of cellular promoters, which may play a significant role in changing the normal GR dependent gene expression. This, for instance, can affect the regulation of cytokine expression (Kino et al., 1999) .
Recently, complex formation between Vpr, GR and poly (ADP-ribose) polymerase-1 (PARP-1) has been identified (Muthumani et al., 2006) , which prevents nuclear translocation of PARP-1. This results in a Vpr dependent suppression of the growth promoting transcription factor NF-κB, and therefore may lead to T-cell depletion and immunosupression observed in HIV infected individuals. Thus Vpr can impair nuclear transport of cellular regulatory proteins and thereby gains pleiotropic functions in the complex regulatory network of the immune system. Considering that GR resides in the cytoplasm in its inactive form (Bamberger et al., 1996) , and Vpr has been shown to promote nuclear transport of the preintegration complex (reviewed in: Sherman and Greene, 2002) , one can assume that interaction between Vpr and GR can be central to early steps in the HIV life cycle.
This assumption prompted us to investigate, whether activation of GR in naive PBMCs might be a mechanism to overcome the restriction in HIV replication in these cells. Our results clearly show that activation of GR results in an increase of HIV gene expression in a Vpr dependent manner, most likely by promoting nuclear import of the preintegration complex (PIC), which in turn results in an increase in the number of provirus carrying cells.
Results
In naive PBMCs HIV-1 gene expression is substantially increased upon ligand activation of GR PBMCs were infected with the T-tropic HIV-1 strain NL4-3 pseudotyped with VSV-G to overcome any restriction to virus entry. In accordance with the tropism of the NL4-3 strain, virus replication was restricted to a single round of infection in these cells. Efficacy of virus production was assayed by detection of Gag protein expression by Western blot analysis in total cell lysates at 3 days post infection. Consistent with previous observations Gag proteins were significantly less abundant in naive PBMCs (Fig. 1A , lane 1) compared to PBMCs stimulated with Fig. 1 A, lane 4) . To determine whether activation of GR could increase virus protein synthesis in naive PBMCs, we added the GR ligand dexamethasone at concentrations of 1 μM and 3 µM at 3 h after virus infection. As shown in Fig. 1A (lanes 2 and 3) the Gag protein levels in lysates of PBMCs treated with the ligand were significantly increased. PHA-stimulated PBMCs, which per se are permissive for virus replication, showed prominent HIV-1 gene expression in the absence of the ligand. The observed increase in virus protein synthesis in naive PBMCs after GR ligand addition corresponded to an increase in the number of Gag positive cells seen in immunofluorescence (Fig. 1B) . The same increase in the level of Gag protein was obtained when cells were infected with the M-tropic virus strain NL.Bal without the VSV glycoprotein (Fig. 1C) , thus favouring viral entry by fusion rather than by endocytosis (Aiken, 1997) .
PHA (
In order to demonstrate that activation of GR by addition of ligand per se is not a signal for the cells to enter the cell cycle, we analyzed the DNA content of untreated and dexamethasone treated cells after 48 h by flow cytometry. As clearly shown, the cell cycle profile of naive PBMCs did not change after ligand addition, still showing an accumulation of the cells in the G1 phase of the cell cycle (Fig. 1D) .
The stimulatory effect of the ligand is confined to an early phase in infection and leads to an enhanced level of integrated provirus In order to determine at which step during virus replication GR activation might be required, we added the ligand at different time points after infection and analyzed the cells for Gag expression. As shown in Fig. 2A , the stimulating effect of dexamethasone was only found when the ligand was given at 3 to 7 h after infection.
Because the effect of the ligand proved to be confined to the early phase of the infection cycle, we assumed that ligand treatment could affect reverse transcription or provirus integration or both. In order to differentiate between these options, total cellular DNA was isolated at 24 h after infection and used as template for semiquantitative PCR analysis. The level of reverse transcription was assayed by a nested semiquantitative PCR using gag primers specific for late reverse transcription (see Materials and methods). As shown in Fig. 2B , dexamethasone treatment did not lead to an enhanced signal intensity of the corresponding PCR product. However when we checked the genomic DNA isolated 24 h after infection for integrated proviral DNA by a nested semiquantitative PCR, using human Alu and HIV LTR primers, the signal intensity of the specific PCR product was significantly higher in the samples of ligand treated cells compared to untreated cells (Fig. 2B ). This suggests that ligand treatment increases the number of provirus carrying cells. However as mentioned before, it has been suggested that resting T cells exhibit a block between early and late reverse transcription. In order to exclude that ligand addition overcomes this restriction, we analyzed early and late reverse transcription by real-time PCR. Ligand addition had only marginal effects on the levels of both early and late reverse transcription, although late reverse transcription products were also less abundant in unstimulated PBMCs (Fig. 2C) . However, the fact that especially early reverse transcription is not influenced by ligand addition is an indication that earlier stages of the virus life cycle are unaffected by GR activation. Instead, our data strongly suggest that a step occurring after reverse transcription and prior to integration is affected. In order to substantiate this finding, we analyzed both DNA and protein lysates from cells treated with dexamethasone at different times after infection (Fig. 2D ). HIV protein expression (upper panel) and proviral integration (lower panels) obtained maximal levels when GR was activated 3 to 7 h after infection (Fig. 2D ). Both signals decreased when the ligand was added at later time points indicating that preintegation complexes containing unintegrated viral DNA are probably targeted for degradation. In summary, our data suggest that treatment of cells with a GR ligand overcomes a block in viral replication that exists after reverse transcription and interferes with proviral integration.
Knock-down of GR in a permissive monocytic cell system impairs Gag expression and provirus integration
Taken together our results suggested that activation of GR by a ligand is crucial for an efficient virus replication in naive human PBMCs. Therefore, we anticipated that knock-down of GR in a permissive system should impair HIV gene expression. Because silencing of GR takes 5 to 6 days after lentiviral transduction with an shRNA coding virus, and PBMCs naturally become permissive for HIV during this time in culture, we chose a permissive monocytic cell line (THP-1) to study the effect of GR knock-down on HIV replication. In these cells GR activation had no effect on the levels on HIV gene expression and proviral integration (Fig. 3A) . For the knock down the cells were transduced with a control lentiviral vector or a vector expressing shRNA specific for human GR and were selected for transgene expression by puromycin resistance. After 6 days they were challenged with HIV-1 strain NL4-3 pseudotyped with VSV-G.
The results are shown in Fig. 3B and C. Western blot analysis indicated a strong reduction in GR expression in transgenic cells and a decrease in viral capsid protein expression, compared to control cells transduced with a vector coding for a scrambled shRNA (Fig. 3B) . Accordingly, semiquantitative PCR using genomic DNA from infected cells as templates showed lower levels of integrated proviral DNA in GR-shRNA transduced cells as in control cells (Fig. 3C ). These data substantiate the suggestion that GR can play a significant role specifically early in the HIV life cycle by promoting provirus integration into the host genome. Knock-down of the receptor resulted in a significant reduction in the amount of integrated provirus leading to reduced virus specific gene expression. Activation by a ligand is required for nuclear translocation of GR in naive but not in PHA-stimulated PBMCs
The viral regulatory protein Vpr plays a critical role early in the HIV life cycle. Vpr is part of the incoming viral capsid and becomes part of the preintegration complex (PIC), translocating with PIC into the nucleus after reverse transcription (for a review see: Sherman and Greene, 2002) . During this process Vpr associates with GR, suggesting that activated GR can promote nuclear import of PIC (Heinzinger et al., 1994; Kino et al., 1999; Sherman et al., 2000) .
Thus we asked whether ligand treatment is required in human naive PBMCs to promote nuclear transport of GR. In the absence of hormone, GR was present in the cytoplasm (Figs. 4A and B, left panel) . After addition of the GR specific ligand dexamethasone and a 10 min lag time, the receptor was released from the cytoplasm and translocated into the nucleus (Fig. 4B , middle panel). In contrast, in PHA-stimulated PBMCs, which per se are permissive to HIV replication, GR was constitutively present in the nucleus, independent of hormone stimulation (Fig. 4B. right panel) . The data indicate that ligand dependent activation of GR is required in naive, but not in PHA-stimulated PBMCs to shift the equilibrium in its subcellular localization towards the nucleus.
Furthermore, we asked whether stimulation of PBMCs with a GR ligand was also required for an efficient nuclear translocation of a transiently expressed Vpr. Naive PBMCs displayed a strong cytoplasmic GFP fluorescence when transfected with a plasmid expressing a fusion protein of Vpr and GFP (Fig. 5,  middle panel) . Addition of the GR ligand dexamethasone 20 h after transfection resulted in accumulation of the GFP signal of the fusion protein first at the nuclear membrane and then it also accumulated in the nucleus (Fig. 5 right panel) . In contrast, eGFP was also detected in the nucleus of transfected cells without GR activation by ligand (Fig. 5, left panel) . These data indicate that transiently expressed Vpr and endogenous GR behave in the same manner with respect to their subcellular localization, and both require the presence of a GR ligand for an efficient nuclear transport. This result is consistent with the notion that the virion associated non-structural protein Vpr associates with GR in the cytoplasm of infected cells (Refaeli et al., 1995; Sherman et al., 2000) .
Vpr and activation of GR by ligand are both required to promote infection of naive PBMCs
In the next experiments we asked whether in addition to the ligand dependent activation of GR a functional Vpr is also required for the initiation of a productive infection in nonpermissive, naive PBMCs. However, when naive PBMCs were infected with the isogenic mutant lacking Vpr (Vazquez et al. 2005) , Gag expression was even further reduced as compared to the infection with wild type virus (Figs. 6A and B, upper panel, lanes 1 and 3). Furthermore, ligand treatment could not overcome this restriction (Figs. 6A and B, upper panel, lanes 2 and 4). By semiquantitative PCR analysis using human Alu and HIV LTR primers, we could show that in this case integrated proviral DNA is hardly detectable (Fig. 6B, lower panel, lane 3) and not increased after receptor activation, in contrast to WT virus infected cells (Fig. 6B, lower panel lanes 2 and 4) . Thus both, Vpr and ligand activation of the receptor are required for an efficient initiation of a productive infection in these cells. In contrast, Gag protein levels are reduced after receptor activation in PHA-stimulated PBMCs (Fig. 6C, lanes 3 and 4) and the differences between with WT virus and Vpr-deficient virus were no longer apparent (Fig. 6C, lanes 3 to 6) . Note that also the levels of reverse transcription remained unaffected by the addition of ligand, whether stimulated PBMCs were infected either with WT virus or the mutant lacking Vpr (Fig. 6D ).
Rat cells with a constitutive cytoplasmic localization of GR behave identical to PBMCs
Our data suggest that in naive PBMCs the efficacy of virus production is dependent on an activation step by a GR ligand prior to integration. Likely, this activation step is important to promote transport of GR in a complex with PIC into the nucleus. To substantiate this relation we included in our studies a rat glioma cell line (C6D8), completely unrelated to PBMCs, but showing the same constitutive cytoplasmic GR localization as naive PBMCs. In the absence of hormone, the cells predominantly harbored GR in the cytoplasm (Fig. 7A, upper panel) . Addition of dexamethasone induced a nuclear translocation of the receptor within a short time range (Fig. 7A, lower panel) . Based on this observation, we examined whether the ligand induced translocation of GR in these cell had also an effect on the efficacy of HIV-1 gene expression.
Cells were also infected with VSV-G pseudotyped HIV-1 to overcome the restriction in HIV-1 entry in these rat cells. Viral gene expression was also monitored by detection of capsid protein expression by Western blot analysis. Total cell lysates were also analyzed at 3 days postinfection. In order to exclude another downstream block in the viral replication cycle in C6D8 cells, e.g. impaired maturation of the virus at the plasma membrane, as shown for other rodent cell systems (Bieniasz and Cullen, 2000) ; (Mariani et al., 2000) , we also analyzed the infected cells by thin section electron microscopy (EM). The EM images revealed budding structures and mature virus particles with typical lentivirus cone shaped cores inside the virus shells. However, in untreated C6D8 cells virus particles were only rarely detected (not shown). This result precludes the presence of a specific assembly block for HIV-1 in C6D8 cells.
To monitor the effect of GR activation, we added dexamethasone (1 µM) to infected C6D8 cells at 3 h postinfection. Addition of the GR ligand to these nonpermissive cells increased the levels of both, total virus specific RNA and capsid proteins dramatically ( Fig. 7B and C lane 2) .
In order to determine if provirus integration was affected in the nonpermissive cells we analyzed the genomic DNA for the amounts of integrated provirus 24 h after infection using a nested semiquantitative PCR (Keppler et al., 2002) . The results show that untreated cells contained far less copies of proviral DNA than cells after receptor activation (Fig. 7D, lanes 1 and 2) . This is a strong indication that the block in these cells, which is overcome by activation of GR, likely exists before integration as seen in naive PBMCs. Additional support for this notion was obtained from Tat transactivation experiments, where in these rat cells no defects in the expression of appropriate reporter constructs were detected (not shown).
Furthermore, infection with the Vpr deletion mutant did not rescue Gag expression, rather even further reduced levels were obtained, similar to the results seen in naive PBMCs (data not shown). Thus both, Vpr and receptor activation by the ligand are required for an efficient initiation of a productive infection in these cell types.
Discussion
Our studies show that activation of the glucocorticoid receptor by the ligand dexamethasone overcomes restriction in HIV-1 replication in freshly isolated PBMCs. The finding underscores the critical role of this nuclear receptor in the HIV-1 life cycle. GR has been discussed to promote HIV-1 replication by stimulating provirus transcription either directly by binding to a putative GR responsive element in the long terminal repeat (Furth et al., 1990; Ghosh, 1992; Mitra et al., 1995) or indirectly by enhancing the effects of cytokines and transcription factors (Kinter et al., 2001) . A major basis of this stimulatory effect is the physical interaction of GR with the accessory viral protein Vpr (Sherman et al., 2000) . Vpr has been described also to interact with other transcription proteins, namely Sp1 (Wang et al., 1995) , TFIIB (Agostini et al., 1999) and to recruit p300/ CBP (Felzien et al., 1998) . Thus Vpr can act as a co-activator of the glucocorticoid receptor, providing a backbone for the formation of a large transcriptional complex to promote provirus transcription (Kino et al., 1999) .
Although, we cannot exclude that activation of GR in PBMCs to some extent also enhances transcription of the HIV-1 provirus, our data rather suggest that activated GR influences an early step in the HIV-1 life cycle, prior to provirus transcription. As shown by a nested semiquantitative PCR using primers specific for late reverse transcription products, the signal was identical whether or not the cells had been treated with dexamethasone. Furthermore, real-time PCR indicated that ligand treatment had no influence on the level of early reverse transcription products, but increased significantly the PCR signal identifying viral genomes integrated into the host genome. It suggests that ligand treatment does not affect virus entry and reverse transcription, but increases the number of provirus copies. The effect of ligand treatment was confined to a time period early after infection of PBMCs, further substantiating that the effect of GR activation is not based on an enhanced provirus transcription. Our data confirm the statement of others that HIV-1 replication in PBMCs is blocked prior to integration (Sonza et al., 1996) , but we suggest that a block exists not before but after the step of reverse transcription. Identical results were obtained when the cells were infected with the M-tropic NL4-3 derivative NL.Bal (Mariani et al., 2001) , indicating that our finding does not reflect an artificial response specific for VSV-pseudotyped HIV-1.
The increase in provirus copies seen upon ligand treatment was only observed when PBMCs were infected with virus containing a functional Vpr. It substantiates the critical role of Vpr in nuclear translocation of PIC. Vpr is packaged in the progeny virions at high copy numbers (Cohen et al., 1990) and it was shown to be indispensable for nuclear localization of viral nucleic acids in non-dividing cells (Heinzinger et al., 1994) . Vpr was found to dock at the nuclear envelope and to interact with importin-α (Vodicka et al., 1998; Fouchier et al., 1998; Nitahara-Kasahara et al., 2007) , suggesting that Vpr interacts with the cellular import machinery to facilitate translocation of PIC into the nucleus. Our data extend these observations showing that efficient provirus formation in PBMCs depends not only on the fact that the virus contains a functional Vpr but also that GR is activated by a ligand. Conversely, ligand treatment was inefficient in infections with a virus lacking Vpr. We assume that nuclear translocation of PIC in PBMCs utilizes pathways regulating nuclear import of GR. Consistent with this notion, PBMCs not treated with dexamethasone harboured the receptor in the cytoplasm, whereas in presence of the ligand the receptor accumulated in the nucleus. This not necessarily implies that Vpr-GR interaction is not functional in the absence of a ligand. It was well demonstrated that binding of PARP-1 to Vpr requiring complex formation with GR takes place in the absence of a GR ligand (Muthumani et al., 2006) . This step impairs nuclear entry of PARP-1 and suppresses NF-κB and thereby contributes to the immunosuppressive action of the virus. Thus, interaction between Vpr and GR can be a gain of function in a ligand dependent and a ligand independent manner, both of which affect the subcellular localization of viral and cellular constituents. In a combined action these mechanisms could significantly enhance virus production.
Our data support suggestions of previous reports that a strong functional cooperation between Vpr and GR in regulating nucleo-cytoplasmic trafficking in the HIV-1 life cycle is required.
Treatment of PBMCs with dexamethasone only led to an efficient provirus integration when the ligand was given within a time period shortly after infection. It suggests that the ligand dependent effect competes with processes withdrawing incoming cores and viral nucleic acid from the infection cycle. Zhou et al. (2005) have shown that in resting CD4+ T cells, virus decay is due to infection-induced apoptosis and intracellular degradation before and after the completion of reverse transcription. The functional half life of full-length, integration competent reverse transcripts in these cells was about 24 h. In addition to the degradation pathway, HIV infection itself could trigger processes that may change the intracellular environment and signalling pathways in a way, that the cells become insensitive to the action of GR ligands. Further studies monitoring the fate of incoming virus particles in relation to the functional status of GR could help to explain these results.
Whereas freshly isolated PBMCs showed a clear correlation between GR activation, extent of provirus integration, and the subsequent expression levels of newly synthesized viral capsid proteins, all of which demanded the presence of a functional Vpr, this correlation was lost in cells which had been stimulated with the mitogen PHA for 24 h. This corresponds to the notion that resistance to the establishment of productive infection by HIV-1 in freshly isolated PBMCS is abolished when the monocytes are stimulated to mature and differentiate (Fear et al., 1998; Sonza et al., 1996; Kimata et al., 1998; Mwaengo and Novembre, 1998) . As shown here, PHA-stimulated PBMCs efficiently produced viral capsid proteins at equal levels whether or not they were incubated with the GR ligand dexamethasone, even when the virus lacked a functional Vpr.
The factors determining this dramatic change in sensitivity to infection with HIV-1 are not known. Consequences of mitogen stimulation are complex, including activation of proliferation and changes in cytokine expression (Poindexter et al., 2005) . These changes may also apply for the relief of the recently described restriction in resting T cells caused by APOBEC3G (Chiu et al., 2005) . Possibly, ligand enhanced provirus integration requiring Vpr and GR is a pathway adjusted specifically to environmental conditions in peripheral mononuclear blood cells, normally the first cells to come in contact with the virus during natural infection. They can contribute to the establishment of virus reservoirs, crucial to subsequent spread to lymphoid organs and T-helper lymphocytes. Further studies are necessary to determine if the effect described here is specific for a certain subpopulation of PBMCs. But studies on the mechanisms regulating the interaction between Vpr and GR in HIV-1 infection of PBMCs are hampered by the heterogeneity of this cell fraction and moreover by the fact that these cells gradually change their phenotype during cultivation in vitro. These changes made it impossible for us to study the effect of downregulation of GR in freshly isolated PBMCs, as this requires the maintenance of the cultures at a prolonged time period at various growth conditions. In this respect it was of interest to find that a subclone of the rat C6 glioma cell line revealed the same phenotype as freshly isolated PBMCs, namely the requirement of GR activation by ligand for efficient virus production. This offers the opportunity to gain basic insights into this pathway by using this homogenous cell population as an experimental system.
Materials and methods

Cells, transfections, and infections
HeLa P4 cells (Clavel and Charneau, 1994) , stably expressing the CCR5 coreceptor (HeLa P4/CCR5) were kindly provided by M. Alizon (Institut Cochin de Genetique Moleculaire, Paris, France). THP-1 cells and C6 rat glioma cells were obtained from the American Type Culture Collection (ATCC CCL 107; Rockville, MD, USA). The subclone C6D8 was isolated from microtiter plates by limiting dilution (Roser et al., 1991) . HeLa P4 cells, 293T cells and C6D8 cells were maintained in Dulbecco's modified minimal Eagle's medium supplemented with 10% heat-inactivated fetal calf serum, 100 U of penicillin per ml, 100 µg of streptomycin per ml, and 2 mM glutamine. PBMCs from normal HIV-1 seronegative donors were isolated by Ficoll-Hypaque density centrifugation. The cells were washed twice in RPMI 1640 and resuspended to give 1×10 6 cells/ml in RPMI 1640 containing 10% fetal calf serum (FCS) and incubated overnight at 37°C. Non adherent cells were collected and washed once with RPMI 1640 10% FCS. PHA stimulation (10 µg/ml) was done 24 h prior to infection. For cell cycle analysis the CycleTest kit from Becton and Dickinson, Germany was used according to the manufacturer's protocol and the cells were analyzed by flow cytometry.
HIV-1 wild type virus or HIV-1/VSV-G pseudotyped virus were produced in HeLa P4 cells by Lipofectamine (Invitrogen, Germany) aided transfection in 10 cm dishes with 15 µg of HIV-1 pNL4-3 DNA (Adachi et al., 1986) or 15 µg pNL4-3 DNA and 5 µg of a VSV-G expression vector, respectively. This latter plasmid and the plasmid NL.Bal (NL4-3 with the env of Bal) (Mariani et al., 2001) were kindly provided by N. Landau (Salk Institute, San Diego, USA). Pseudotyped virus lacking a functional Vpr was produced by cotransfection of pNL4-3ΔVpr (Vazquez et al., 2005) which was kindly provided by U. Schubert (University of Erlangen, Germany) and the VSV-G expression plasmid. Virus stocks were analyzed by p24 ELISA and stored at − 80°C. PBMCs (1.5 to 2.0 × 10 6 ) were infected with 500 ng of p24 antigen and incubated at 37°C for 3 h. After washing twice with PBS they were resuspended in RPMI 1640 containing 10% FCS and incubated further at 37°C.
For infection of the subclone C6D8 of the C6 Glioma cell line, 2 × 10 6 cells were seeded in 10 cm Petri dishes and cultivated overnight at 37°C. The next day the culture medium was removed and the virus (400 to 500 ng of p24 antigen) was added to the plates. After 3 h the virus was removed and after washing the dishes twice with PBS fresh culture medium was added. Dexamethasone was added 3 h postinfection at the concentration indicated. For transfection of unstimulated PBMCs with eGFP and Vpr-GFP (McDonald et al., 2002) expression vectors, the nucleofector kit (Amaxa, Germany) according to the manufacturer's protocol was used. Briefly, 2 × 10 6 PBMCs isolated as above were transfected with 1 µg of plasmid DNA of either eGFP or Vpr-GFP. After 20 h cells were left untreated or treated with dexamethasone (1 µM) and analyzed by confocal microscopy.
The lentiviral control vector DNA (SHC002) containing a scrambled sequence and the vector DNA for silencing human GR (SHDNAC-TRC0000019319) were obtained from Sigma, Germany. Lentiviral particles were produced in 293T cells by cotransfection of 3 µg vector DNA, 3 µg packaging construct R8.91 obtained from D. Trono, University of Geneva, and 0.5 µg VSV-G expression construct. Viral particles were harvested after 48 h and stored at − 80°C. For silencing of GR, THP-1 cells were infected with 500 ng (p24) lentiviral vector and selected for stably transduced cells with puromycin. After 6 days the cells were challenged with HIV/VSV-G pseudotypes. Genomic DNA was prepared 24 h after infection and cell lysates were prepared after 48 h for protein analysis.
Analysis of expression products
HIV antigens were analyzed using a quantitative ELISA detecting the viral CA protein (Konvalinka et al., 1995) . For Western Blot analysis, cell extracts were separated on 12.5% SDS-polyacrylamide gels and proteins were transferred to nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) by electroblotting. Membranes were blocked with 10% low fat dry milk in PBS for 1 h and subsequently reacted with a monoclonal antibody (183) against HIV-1 CA obtained from the NIH AIDS Research and Reference Reagent Program. The antibody was purified from cell culture supernatant by protein A affinity chromatography and was concentrated to about 8 to 10 mg/ml. The antibody was diluted 1:2000 to 1:4000 in PBS containing 5% low fat dry milk, 0.05% Tween 20. Incubation was carried out overnight at room temperature with shaking. After washing three times with PBS containing 0.05% Tween 20, peroxidase-conjugated anti-rabbit antibodies (Dianova, Germany) were used as secondary antibodies and incubated for 2 h at room temperature. Immune complexes were visualized using enhanced chemiluminescence (ECL; Amersham, Germany) according to the manufacturer's instructions.
Northern blot analysis
Total RNA was isolated from 5 × 10 6 to 1 × 10 7 cells using trizol reagent (Invitrogen, Germany) as suggested by the manufacturer. 10 to 20 µg RNA were loaded onto formaldehyde containing 1.2% agarose gels. The RNA was transferred to Hybond membranes (Amersham, Germany) by capillary transfer. 32 P-labeled probes were made by random priming using the NcoI/XhoI fragment from pNL4-3, which allowed detection of all three classes of HIV-1 specific RNAs.
Detection of integrated proviral DNA
A semiquantitative nested PCR for the specific amplification of HIV-1 proviral DNA integrated into the human or rat genome was used. For PBMCs a human Alu primer was used (5′-CTCAC-GCCTGTAATCC-CAGCA-3′) and for the rat genome an oligonucleotide primer BC1-A (5′-GGATTTAGCTCAGTGG-TAGA-3′) from a consensus sequence that is highly abundant in the rat genome was used (Chun et al., 1997) . Genomic DNA was extracted from infected cells 24 h after infection using DNAzol (Invitrogen, Germany). The PCR reactions were done as described previously (Keppler et al., 2002) . Briefly, the first PCR amplification was done with the HIV-1 LTR primer (5′-AGGCAAGCTT-TATTGAGGCTTAAGC-3′) and the BC1-A primer or the human Alu primer. The reaction was run with the following program: (a) 3 min at 94°C, (b) 30 cycles of 30 s at 94°C, 30 s at 57°C, and 4 min at 72°C, and (c) 10 min at 72°C. A second nested PCR amplification, which allows amplification of a 357-basepair LTR fragment, was performed by using 1 µl of the first reaction with internal HIV-1 LTR primers NI-2 5 and NI-2 5, (5′-CACACA-CAAGGCTACTTCCCT-3′), and NI-2 3, (5′-GCCACTCCCCA-GTCCCGCCC-3′ (Chun et al., 1997) . This second PCR was performed using the same PCR conditions as for the first one, except that the annealing temperature was raised to 60°C, the extension time was 1 min, and amplification was run for 25 cycles. In control reactions fragments of the rat β-globin gene using the primer pair (5′-TGACTCGCAACCTCAGGAA-3′and 5′-GGAT-CCACATGCAGCTTG-3′) and of the human β-globin gene using the primer pair (5′-CGAATGATTGCATCAGTGTGGAAGTC-3′ and 5′-GCAGAATGGTAGCTGGATTGTAGC-3′) were amplified. PCR products were analyzed by ethidium bromide/agarose gel electrophoresis.
Analysis of reverse transcription
Reverse transcribed products were detected by a nested PCR targeted to the Gag region. For the first PCR the following primers were used: Nts 1330-1351 5′-CCACAAGATTTAAATACCAT-GC-3′ and Nts 1819-1840 5′-GACATGCTGTCATCATTTCT-TC-3′. The nested PCR was done with the following primer pair: 5′-CCATCAATGAGGAAGCTGCAG-3′, 5′-GGTTCCTTTGG-TCCTTGTCTTA-3′ representing Nts 1400-1420 and 1641-1664, respectively. Both reactions were run with the same protocol, except that for the nested PCR the cycle number was increased from 14 to 29. (a) 3 min at 95°C, (b) 14 cycles of 30 s at 95°C, 30 s at 56°C, and 4 min at 72°C, and (c) 10 min at 72°C .
Real-time PCR quantification of reverse transcripts
Total DNA was prepared at the 24 h postinfection. Early and late HIV-1 reverse transcription products were quantified using specific primer and probe combinations (Chiu et al., 2005) . Reaction mixtures (10 µl) contained Platinum PCR MasterMix (Invitrogen), 300 nM forward primers, 900 nM reverse primers and 200 nM probe and 1 µl of total DNA. PCR was performed for 3 min at 95°C followed by 40 cycles of 15 s at 95°C, and 30 s at 60°C using an ABI 7500 (Applied Biosystems). Detection of early reverse transcripts was done with primers of R/U5 region (forward: 5′-GGCTAACTAGGGAACCCACTGC-3′, reverse: 5′-AACAGACGGGCACACACTACT-3′, probe: 5′-(6~FAM)-TAAGCCTCAATAAAGCTTGCCTTGAGTGCTC-(BHQ1a)-3′; and of late reverse transcripts with primers of U5/Gag region (forward: 5′-AGATCCCTCAGACCCTTTTAGTCA-3′, reverse: 5′-CTTTCGCTTTCAAGTCCCTGTT-3′, probe: 5′-(6~FAM)-TGGAAAATCTCTAGCAGTGGCGCCC-(BHQ1a)-3′. Each sample was tested in triplicates, and the results were normalized using amplification of the same genomic DNA with human β-globinprimers (HBG-forward: 5′-CTTAATGCCTTAA-CATTGTGTATAA-3′, HBG-reverse: 5′-GAATATGCAAA-TAAGCACACATATAT-3′, HBG-probe: 5′-(6~FAM)-ACTTTACACAGTCTGCCTAGTACATTAC-TAMRA-3′).
Immunofluorescence and confocal microscopy
Infected PBMCs were washed once with PBS and fixed for 10 min in − 20°C methanol/acetone. After rehydration in PBS, the cells were incubated with a mouse monoclonal anti-CA antibody followed by DTAF labeled goat anti-mouse antibodies (Dianova, Germany). C6D8 cells were washed once with PBS and fixed for 10 min in − 20°C methanol/acetone blocked with 2% normal goat serum, incubated with rabbit anti-GR antibodies, followed by FITC labeled goat anti-rabbit antibodies (Dianova, Germany). Uninfected PBMCs were fixed with acetone (− 20°C) blocked with 2% normal donkey serum and labelled with monoclonal mouse antibodies to vimentin (V9, Boehringer, Germany) and rabbit antibodies to human GR (E20, Santa Cruz, U.S.A.). Donkey anti-mouse Alexa 488 and donkey anti-rabbit Alexa 555 (Molecular Probes, USA) were used as secondary antibodies. DNA was stained with DRAQ 5. Optical sections were produced with a Zeiss Meta Confocal Microscope (Zeiss, Germany). Life images of transfected PBMCs were also obtained with this microscope.
